<DOC>
	<DOCNO>NCT02799706</DOCNO>
	<brief_summary>The primary objective trial ass GnRH antagonists combination external beam radiation therapy improve progression free survival ( progression biological , clinical , death ) compare GnRH agonists combination external beam radiation therapy . Secondary objective include : - documentation effect GnRH antagonists clinically significant cardiovascular event subgroup patient high risk event baseline ; - documentation side effect quality life , I-PSS urinary tract infection ; - assessment relative treatment effect secondary efficacy endpoint ( clinical progression , time next line systemic therapy , time therapy , overall cancer specific survival ) PSA 6 month end RT .</brief_summary>
	<brief_title>Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection Patients With Very High Risk Localized Locally Advanced Prostate Cancer</brief_title>
	<detailed_description>Phase IIIb randomize stratified open-label comparative 2-arm superiority study pre-set non-inferiority boundary . Registered GnRH antagonist , degarelix , give dose 240 mg give two subcutaneous injection 120 mg concentration 40 mg/mL day 1 , follow 80 mg give one subcutaneous injection concentration 20 mg/mL every 28 day ( ±2 day ) . External beam radiotherapy ( EBRT ) total dose 78-80 Gy , deliver one daily fraction , five day week , start d1 month 6 androgen deprivation therapy per institution policy . The irradiation reference therapy arm . The minimum duration androgen deprivation GnRH agonist antagonist therapy 18 month . For patient , duration therapy must elect upfront treat physician among three possible option : 18 , 24 36 month . The institution shall also declare upfront duration neoadjuvant treatment intend deliver patient ( 0 6 month ) . The primary endpoint progression-free survival define time day randomization death , clinical biochemical progression , whichever come first . Where - PSA progression base Phoenix definition , i.e . rise 2 ng/mL nadir PSA ( Ref . 17 ) confirm second value measure minimum 3 month later - Clinical progression define onset obstructive symptom require local treatment demonstrate caused cancer progression evidence metastasis detect clinical symptom confirm image - Start another line systemic therapy absence progression - Death due cause Secondary endpoint : - Clinical progression-free survival - Time next systemic anticancer therapy ( include secondary hormonal manipulation ) - Proportion patient switch GnRH antagonist GnRH agonists total effective duration treatment originally allocate drug . - Overall survival - Cancer specific survival - PSA six month completion RT Safety score CTCAE version 4.0 . The major safety endpoint study - incidence clinical cardiovascular event - CCE ( i.e . arterial embolic thrombotic event , hemorrhagic ischemic cerebrovascular condition , myocardial infarction , ischemic heart disease ) patient cardiovascular event enter trial without event . - Incidence urinary tract infection</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm diagnosis prostate adenocarcinoma PSA ≥ 10 ng/ml two follow 4 criterion : PSA ≥ 20 ng/ml , Gleason sum ≥ 8 , cN1 ( regional LN short axis length &gt; 10mm CT scan MRI ) pathologically confirm lymph node ( pN1 ) , cT3T4 ( MRI core biopsy ) ( i.e . If PSA≥ 20 ng/ml one 3 risk factor need ) M0 standard image workup ( see chapter 6.1.1.1 ) Testosterone ≥ 200 ng/dl Adequate renal function : calculated creatinine clearance ≥ 50 mL/min ( Appendix D ) Magnesium potassium within normal limit institution correct within normal limit prior first dose treatment . Patients prolonged QTintervals due prescribed Class IA ( quinidine , procainamide ) Class III ( amiodarone , sotalol ) antiarrhythmic medication must carefully evaluate GnRHagonist GnRH antagonist use , drug may prolong QTinterval . WHO Performance status 01 Age ≥ 18 ≤ 80 year Participants partner childbearing potential must use adequate birth control measure , define investigator , study treatment period least 3 month last dose study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Previous use androgen deprivation therapy ( ADT ) , antiandrogens . 5alpha reductase inhibitor allow interrupted 6 month prior enter study History severe untreated asthma , anaphylactic reaction severe urticaria and/or angioedema . Hypersensitivity towards investigational drug The following biological parameter : AST , ALT , total bilirubin , prothrombin time , serum albumin upper level normal range No severe hepatic impairment ( Child Pugh C ) History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption protocol treatment . History pituitary adrenal dysfunction Uncontrolled diabetes mellitus History ulcerative colitis , Crohn 's Disease , ataxia , telangiectasia , systemic lupus erythematous , Fanconi anemia . Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) class III IV heart disease cardiac ejection fraction measurement &lt; 50 % baseline Coronary revascularization ( PCI multivessel CABG ) , carotid artery iliofemoral artery revascularization ( percutaneous surgical procedure ) within last 30 day prior enter trial Certain risk factor abnormal heart rhythms/QT prolongation : torsade de pointes ventricular arrhythmia ( e.g , heart failure , hypokalemia , family history long QT syndrome ) , QT correct QT ( QTc ) interval &gt; 450 m baseline , intake medication prolong QT/QTc interval Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) ; patient history hypertension allow provide blood pressure control antihypertensive treatment . Prior history malignancy prostate adenocarcinoma ( except patient basal cell , squamous cell carcinoma skin ) , patient free malignancy period 3 year prior first dose study drug ( ) . Prior history bladder cancer exclude patient . Prior radical prostatectomy ( TURP suprapubic adenomectomy benign prostatic hyperplasia allow ) Prior brachytherapy radiotherapy would result overlap radiotherapy field Any contraindication external beam radiotherapy Patients significantly alter mental status prohibit understand study psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule condition , opinion investigator , would preclude participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>high risk localize prostate cancer</keyword>
	<keyword>locally advanced prostate cancer</keyword>
</DOC>